BioSpace News Archive

Arix Bioscience plc (LSE:ARIX) (“Arix”), a global venture capital company investing in and building breakthrough biotech companies, today announces that Christian Schetter, PhD, currently Entrepreneur in Residence at Arix, has been appointed as a Managing Director.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share.